24 May 2022 in Chinese Medicine
Background: Many studies about depression have focused on the dysfunctional synaptic signaling in the hippocampus that drives the pathophysiology of depression. Radix Bupleuri has been used in China for over 2000 years to regulate liver-qi. Extracted from Radix Bupleuri, Saikosaponin D (SSD) is a pharmacologically active substance that has antidepressant effects. However, its underlying mechanism remains unknown. Materials and methods: A chronic unpredictable mild stress (CUMS) paradigm was used as a rat model of depression. SD rats were randomly assigned to a normal control (NC) group or one exposed to a CUMS paradigm. Of the latter group, rats were assigned to four subgroups: no treatment (CUMS), fluoxetine-treated (FLU), high-dose and low-dose SSD-treated (SSDH and SSDL). SSD was orally administrated of 1.50 mg/kg and 0.75 mg/kg/days for three weeks in the SSDH and SSDL groups, respectively. Fluoxetine was administrated at a dose of 2.0 mg/kg/days. SSD’s antidepressant effects were assessed using the open field test, forced swim test, and sucrose preference test. Glutamate levels were quantified by ELISA. Western blot and immunochemical analyses were conducted to quantify proteins in the Homer protein homolog 1 (Homer1)-metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) pathways in the hippocampal CA1 region. To measure related gene expression, RT-qPCR was employed. Results: CUMS-exposed rats treated with SSD exhibited increases in food intake, body weight, and improvements in the time spent in the central are and total distance traveled in the OFT, and less pronounced pleasure-deprivation behaviors. SSD also decreased glutamate levels in CA1. In CA1 region of CUMS-exposed rats, SSD treatment increased mGluR5 expression while decreasing Homer1 expression. SSD also increased expressions of postsynaptic density protein 95 (PSD95) and synapsin I (SYP), and the ratios of p-mTOR/mTOR, p-p70S6k/p70S6k, and p-4E-BP1/4E-BP1 in the CA1 region in CUMS-exposed rats. Conclusions: SSD treatment reduces glutamate levels in the CA1 region and promotes the expression of the synaptic proteins PSD-95 and SYP via the regulation of the Homer1-mGluR5 and downstream mTOR signaling pathways. These findings suggest that SSD could act as a natural neuroprotective agent in the prevention of depression.
12 October 2021 in The Anatomical Record
COVID‐19 (coronavirus) has spread all over the world with a high infection rate. Currently, there are no targeted therapeutic drugs for COVID‐19 as well as for stress induced by COVID‐19. The unpredictable events of COVID‐19 can trigger feelings of fear, worry, or unease in people, leading to stress‐related disorders such as depression and anxiety. It has been reported that individuals, including COVID‐19 patients, medical staff, and ordinary people, are under both physical and psychological pressure, and many of them have developed depression or anxiety during this pandemic. Traditional Chinese medicine (TCM) has been widely used in treating depression with relatively better safety and efficacy and may have an important role in treating stress‐related disorders induced by COVID‐19. In this review, we collected the common TCM treatment methods including Qigong, Acupuncture, Five Elements Musical Therapy, Five Elements Emotional Therapy, and Chinese herbal medicine from the databases of PubMed and the China National Knowledge Internet to illustrate the effect of TCM on depression. The better knowledge of TCM and implementation of TCM in COVID‐19 clinics may help to effectively improve depression induced by COVID‐19, may assist people to maintain a healthy physical and mental quality, and may alleviate the current shortage of medical resources.
11 February 2026 in Chinese Medicine
The complexity of traditional Chinese medicine (TCM), with its numerous components, targets, and varying efficacy, presents challenges for current evaluation methods. Most existing methods rely on single, qualitative indicators, which provide limited insight into the overall quality. These methods fail to fully capture the intrinsic quality, efficacy, and safety of Chinese medicine, highlighting the need for more advanced biological evaluation techniques. Target-based drug discovery has become the primary approach in pharmaceutical research and development, where drug targets play a crucial role in guiding the entire process. As our understanding deepens, integrating artificial intelligence (AI) with multi-omics technologies has opened new possibilities for enhancing treatment precision. AI’s efficiency in identifying drug targets marks a significant leap forward in drug discovery, facilitating the modernization of the drug development process. Meanwhile, omics technologies offer distinct advantages, such as comprehensive controllability, strong correlations with clinical efficacy and safety, and a holistic view of the overall quality of Chinese medicine. These technologies provide an effective and rational approach for evaluating the quality of Chinese medicine and are instrumental in developing quality control systems for TCM. Consequently, combining AI with multi-omics methods is poised to become a key direction for future research into the discovery of targets for antidepressant Chinese medicine. Graphical
10 February 2026 in Frontiers in Cardiovascular Medicine
Introduction: Danggui-Chuanxiong is a classic Chinese medicine formulation clinically employed for atherosclerosis (AS) management by modulating lipid metabolism and improving hemodynamic properties. Materials and methods: Integrated network pharmacology, molecular docking and molecular dynamics simulation approaches were employed to elucidate the material basis and therapeutic mechanisms of DG-CX in AS treatment, and validated by subsequent experiments. The regulatory effects of DG-CX on the c-Abl/YAP signaling pathway were comprehensively assessed through integrated histopathological and molecular analyses. Results: Network pharmacology analysis identified sterols, stigmasterol, and wallichilide as the principal bioactive constituents of DG-CX. Furthermore, molecular docking validated that VEGFR2 and PTGS2 are the core targets, which are potentially mediated through c-Abl/YAP signaling pathway, consistent with strong binding affinities. Molecular dynamics simulations of the protein-ligand complexes revealed that the PTGS2-FER and VEGFR2-β-sitosterol complexes exhibited stable binding, with favorable hydrogen bonding interactions. Our research results show that DG-CX can reduce the body weight of AS mice, improve lipid metabolism disorders, and upregulate the expression of NO/NOS, AngII/AT1R, and PGI2 ( p < 0.01), inhibit the expression of VEGFR2 and PTGS2 mRNA ( p < 0.05 or p < 0.01), and the expression of the Interα5β1/c-Abl/YAP pathway. Conclusions: Validation using network pharmacology, molecular docking, molecular dynamics simulation and in vivo studies suggested the efficacy of DG-CX in improving vascular endothelial function and exerting anti-AS effects by inhibiting the c-Abl/YAP signaling pathway.